Journal article
Crossover trial of gabapentin and memantine as treatment for acquired nystagmus
Annals of neurology, Vol.67(5), pp.676-680
05/2010
DOI: 10.1002/ana.21991
PMCID: PMC3064518
PMID: 20437565
Abstract
We conducted a masked, crossover, therapeutic trial of gabapentin (1,200mg/day) versus memantine (40 mg/day) for acquired nystagmus in 10 patients (aged 28-61 years; 7 female; 3 multiple sclerosis [MS]; 6 post-stroke; 1 post-traumatic). Nystagmus was pendular in 6 patients (4 oculopalatal tremor; 2 MS) and jerk upbeat, hemi-seesaw, torsional, or upbeat-diagonal in each of the others. For the group, both drugs reduced median eye speed (p < 0.001), gabapentin by 32.8% and memantine by 27.8%, and improved visual acuity (p < 0.05). Each patient improved with 1 or both drugs. Side effects included unsteadiness with gabapentin and lethargy with memantine. Both drugs should be considered as treatment for acquired forms of nystagmus.
Details
- Title: Subtitle
- Crossover trial of gabapentin and memantine as treatment for acquired nystagmus
- Creators
- Matthew J Thurtell - Neurology Service, Veterans Affairs Medical Center, Cleveland OH, USAAnand C JoshiAlice C LeoneRobert L TomsakGregory S KosmorskyJohn S StahlR John Leigh
- Resource Type
- Journal article
- Publication Details
- Annals of neurology, Vol.67(5), pp.676-680
- DOI
- 10.1002/ana.21991
- PMID
- 20437565
- PMCID
- PMC3064518
- NLM abbreviation
- Ann Neurol
- ISSN
- 0364-5134
- eISSN
- 1531-8249
- Publisher
- United States
- Grant note
- R01 EY006717-25 / NEI NIH HHS R01 EY006717 / NEI NIH HHS EY06717 / NEI NIH HHS
- Language
- English
- Date published
- 05/2010
- Academic Unit
- Neurology; Ophthalmology and Visual Sciences
- Record Identifier
- 9983980081002771
Metrics
41 Record Views